Dupilumab safe for long-term use to treat moderate to severe asthma

Dupilumab appeared safe for long-term use among patients with moderate to severe asthma or oral corticosteroid-dependent severe asthma, according to data from the TRAVERSE continuation study.
“The proportion of patients reporting treatment-emergent adverse events throughout the TRAVERSE continuation study was lower than that observed in the parent studies,” Jorge F. Maspero, MD, medical director of Fundación CIDEA in Buenos Aires, Argentina, and colleagues wrote.
The single-arm, multicenter, open-label 3b study included 393 participants (mean age, 52.1 years; 58.8% female) with

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.